Fiji vs Uruguay: Prostate cancer death rate in men
Fiji
18.25 deaths per 100,000 people
in 2012
Uruguay
18.16 deaths per 100,000 people
in 2022
Fiji rank
27th
Uruguay rank
28th
Prostate cancer death rate in men over time
- Fiji
- Uruguay
How they compare
Fiji currently reports 18.25 deaths per 100,000 people against 18.16 deaths per 100,000 people in Uruguay, a difference of 0.09 deaths per 100,000 people.
Across all 11 years both countries report, Uruguay has been ahead every year.
Fiji ranks 27th and Uruguay ranks 28th of 111 countries.
Uruguay has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Fiji | Uruguay | Difference | Ahead |
|---|---|---|---|---|
| 1970s | 3.02 deaths per 100,000 people | 23.3 deaths per 100,000 people | 20.28 deaths per 100,000 people | Uruguay |
| 2000s | 14.54 deaths per 100,000 people | 26.96 deaths per 100,000 people | 12.42 deaths per 100,000 people | Uruguay |
| 2010s | 18.25 deaths per 100,000 people | 23.46 deaths per 100,000 people | 5.21 deaths per 100,000 people | Uruguay |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prostate cancer death rate in men, Fiji or Uruguay?
- Fiji, at 18.25 deaths per 100,000 people against 18.16 deaths per 100,000 people in Uruguay as of 2012.
- What is the difference in prostate cancer death rate in men between Fiji and Uruguay?
- 0.09 deaths per 100,000 people, with Fiji ahead.
- How many years of comparable data are there for Fiji and Uruguay?
- 11 years are reported by both, from 1978 to 2012.
- How do Fiji and Uruguay rank globally for prostate cancer death rate in men?
- Fiji ranks 27th and Uruguay ranks 28th of 111 countries.
- Where does this data come from?
- WHO Mortality Database (2025) β with minor processing by Our World in Data, published as Prostate cancer death rate in men. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Reported deaths from prostate cancer in males in those aged all ages per 100,000 people.